Antares Pharma Inc. said Thursday the FDA has approved its topical gel for the treatment of overactive bladder.

Overactive bladder (OAB) is a type of urinary incontinence and a form which, like urinary incontinence in general, can be associated with a number of factors, including BPH, prostatitis and prostate cancer and their treatments. Although millions of men and women have overactive bladder, few people will admit they have this condition, even to their doctors. An estimated 29.8 million adults aged 40 years or older in the United States have bothersome symptoms of overactive bladder.

The New Jersey-based pharmaceutical company said that the gel will come in a clear, odorless oxybutynin form in a metered pump. Oxybutynin is used to treat overactive bladder and is applied once daily to the thigh, abdomen, upper arm or shoulder.

Read more

Researchers at Brunel and Manchester universities are working on a technology to detect liquid and leakage in adult diapers and alert the user via a signalling device.

The vibrating version of the underwear is currently half way through clinical trials at the Bristol Urological Centre following a successful pilot. So far it has only been designed for women, who make up two thirds of incontinence sufferers.

As if there are not enough reasons to avoid fake drugs and medications new evidence now shows the existence of paint and rat poison in fake erectile dysfunction pills.

Fraudsters use commercial-grade paint to mimic the erectile dysfunction drug’s trademark blue color, and then pack the pills with toxins like boric acid, speed, and even rat poison.

Men with prostate cancer who are considering hormone therapy or who are already on hormone therapy may be encouraged by the results of a new study appearing in the Journal of the American Medical Association. The meta-analysis found that hormone therapy did not increase the risk of cardiovascular deaths, plus it showed a lower risk of prostate cancer –specific death and death from all causes among men on hormone therapy. Continue Reading »

For men with prostate cancer who are being treated with hormone therapy, news of a potentially dangerous side effect of hormone therapy associated with their prostate cancer treatment suggests it’s time to talk to their doctor. A large study conducted by researchers at Memorial-Sloan Kettering Cancer Center found that older men with prostate cancer who received hormone therapy had a 56% greater chance of developing a blood clot in their lungs, veins, or arteries compared with men who had not received the treatment. According to Dr. Behfar Ehdaie, the study’s lead author, “By no means is this a trivial risk.” A man’s risk of developing a blood clot increased the longer he was on hormone therapy.

Read more

Ehdaie B et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer 2011 Nov 9; online. DOI: 10.1002/cncr.26623

Viagra may provide more than a wake-up to a man’s sex life – it may help the body’s immune system fight cancer, a new study involving mice suggests.

Recent studies show the increased association between red meat and prostate cancer including an increased risk of prostate cancer when meat was grilled at high temperatures. In addition, men who ate the most ground beef were 2.3 times more likely than men who ate none to have aggressive prostate cancer.

Read more

According to a new study published online in the British Journal of Urology International the use of multiple medications at once significantly increases the symptoms of erectile dysfunction and is one of the causes of erectile dysfunction.

The new study, funded by Kaiser Permanente, surveyed 37,712 men from Southern California with diverse backgrounds and found that men taking various medications are likely to have more severe erectile dysfunction. This was part of the California Men’s Health Study, a multiethnic cohort of men ages 46 to 69 who are members of Kaiser Permanente in California.

Read more

Pfizer Inc. (NYSE: PFE) today announced updated study results  for Toviaz (fesoterodine fumarate) for the effectiveness and safety for patients with Overactive Bladder/Incontinence including Nocturnal Urinary Urgency. Treatment for incontinence/OAB with Toviaz was found to be statistically significantly superior to placebo in reducing the number of urinary episodes overnight during sleep hours after 12 weeks of treatment.

Urinary Incontinence is a treatable medical condition caused by involuntary contractions or spasms of the bladder muscle. Overactive bladder symptoms of urgency, frequency or urge urinary incontinence can be bothersome and can have a significant impact on important aspects of people’s lives. Approximately 33 million Americans are estimated to suffer from overactive bladder symptoms. Despite its prevalence, overactive bladder is often unrecognized and untreated.

Read more

According to a study published in the November issue of Urology, overactive bladder (OAB) is prevalent in patients with type 2 diabetes, with the prevalence higher in older patients and those with long-standing diabetes.
Read more